ALLR:NASDAQ, Allarity Therapeutics, Inc.

ALLR stock overview

Allarity Therapeutics, Inc. (ALLR:NASDAQ) closed at $0.915 on October 26, 2026, up 3.41% on the day. The stock trades 50.3% below its 52-week high of $1.84 and 19.0% above its 52-week low of $0.769. Over the past year, it lost 37.7%. Allarity Therapeutics, Inc. is part of the Health Care sector.

Key figures

Price

$0.915

Day change

+3.41%

Volume

174,219

Average volume

104,659

Market cap

14M+

52-week range

$0.769 – $1.84

50-day average

$1.14

200-day average

$1.22

Price action over the past year

In 252 trading sessions since October 24, 2025, ALLR closed higher on 110 days (44%). Its best day was March 6, 2026 (+21.57%) and its worst was October 12, 2026 (-13.13%). The stock moved 10% or more in a single session 13 times.

Recent signals

• Oct 23, 2026: Down 25.6% over 90 days, from $1.23 (Dips & Crashes scanner)
• Oct 23, 2026: Trading sideways between $0.833 and $0.895 over 14 days (Sideways scanner)
• Oct 5, 2026: News catalyst: Biotech (News Catalysts scanner)

ALLR news

• Oct 9, 2026: Here's Why Allarity Therapeutics, Inc. (ALLR) Is a Great 'Buy the Bottom' Stock Now
• Oct 5, 2026: New Valion Bio Board Chair Thomas Jensen Brings Biotech Turnaround Experience to the Advancement of Entolimod
• Sep 30, 2026: Allarity Provides Update on Key Recent Advances Solidifying Drug Response Predictor to Drive Stenoparib's Clinical Development
• Sep 30, 2026: Allarity Provides Update on Key Recent Advances Solidifying Drug Response Predictor® to Drive Stenoparib's Clinical Development
• Sep 28, 2026: Allarity Therapeutics Expands Laboratory Capabilities to Include Proteomics and Cell Line Research
• Sep 15, 2026: Allarity Therapeutics Granted Japanese Patent for Stenoparib DRP® Companion Diagnostic, Further Strengthening Stenoparib Development
• Sep 15, 2026: Allarity Therapeutics Granted Japanese Patent for Stenoparib DRP Companion Diagnostic, Further Strengthening Stenoparib Development
• Sep 11, 2026: Allarity Therapeutics Announces Strategic Capital Allocation for Filing of SPAC Registration Statement

About Allarity Therapeutics, Inc.

Allarity Therapeutics Inc is a clinical-stage, precision medicine company. The company is actively advancing a pipeline of in-licensed oncology therapeutics for patients with difficult-to-treat cancers. Its Drug Response Predictor (DRP) technology refines patient selection and improve clinical outcomes. Its pipeline product includes Dovitinib, Stenoparib, Ixempra.

Similar stocks

• RADX:NASDAQ
• UPC:NASDAQ
• ARAY:NASDAQ
• NCEL:NASDAQ
• QNTM:NASDAQ
• GUTS:NASDAQ
• PLUR:NASDAQ
• ATYR:NASDAQ

Find more stocks like ALLR with the Spikes, Gaps, Breakouts and Performance Tracker scanners.

Based on end-of-day data. For information only, not investment advice.